Twenty-four vs. forty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in interferon alpha monotherapy relapsers with chronic hepatitis C
August-Jörg B, Renner E, Weitz M, Meyenberger C, Hermann R, Henz S, Gonvers J, Dufour J, Borovicka J, Swiss Association for the Study of the Liver. Twenty-four vs. forty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in interferon alpha monotherapy relapsers with chronic hepatitis C. Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology 2003; 133:455-60.
Aug 23, 2003
Twenty-four vs. forty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in interferon alpha monotherapy relapsers with chronic hepatitis C
Aug 23, 2003
Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology 2003; 133:455-60
August-Jörg Barbara S E, Renner Eberhard L, Weitz Manfred, Meyenberger Christa, Hermann Rudolf, Henz Samuel, Gonvers Jean-Jacques, Dufour Jean-François, Borovicka Jan, Swiss Association for the Study of the Liver
more
